TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25291126
Drug: Lactobacilli supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli supplementation (L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, L. delbrueckii subsp. delbrueckii LDD01) for 15 days
Study: 21058198
Drug: Oral formula
Normalized name: L-Formula Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formula with nutrients arginine, RNA, and ω‐3 fatty acids (Group 2)
Study: 11898769
Drug: Low-energy diet
Normalized name: Low-energy diets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy diet with semi-solid meals (2.5 g guar gum)
Study: 2697886
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with ispaghula husk and propantheline (Group B)
Study: 2697886
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment after relapse on placebo
Study: 2697886
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of active treatment
Study: 2697886
Drug: Reinstitution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinstitution of active treatment
Study: 973598
Drug: Pure ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pure ethanol (9.3% w/v aqueous alcohol solution)
Study: 24117692
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (omeprazole and amoxicillin for 5 days followed by omeprazole, clarithromycin and metronidazole for 5 days)
Study: 24117692
Drug: 7-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Study: 24117692
Drug: 10-day standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day standard triple therapy (omeprazole, amoxicillin and clarithromycin)
Study: 16373409
Drug: HCG group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG group (vaginal progesterone after HCG administration)
Study: 14626871
Drug: Maximum recommended
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum recommended dose of mepivacaine
Study: 8618582
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg famotidine twice daily
Study: 28141622
Drug: Avisetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avisetron (8 mg)
Study: 26556032
Drug: Online program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online program plus weekly email prompts
Study: 24180166
Drug: Licorice lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice lozenges (Group A)
Study: 21470071
Drug: Zaltoprofen (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaltoprofen (80 mg t.i.d.)
Study: 19447425
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (300 mg orally daily)
Study: 14706765
Drug: Low-dose synthetic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose synthetic conjugated estrogens A (SCE-A), 0.3 mg once daily for 16 weeks
Study: 14706765
Drug: Low-dose synthetic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose synthetic conjugated estrogens A (SCE-A)
Study: 7758607
Drug: Digoxin in
Normalized name: digoxin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin in combination with diuretics
Study: 7758607
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of digoxin and diuretics with a blocker of the renin‐angiotensin system (kapothenum)
Study: 3058101
Drug: 2% MK-927
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% MK-927 ophthalmic solution
Study: 25873370
Drug: Polyphenon E
Normalized name: Polyphenon E
DrugBank: Sinecatechins (DB01266)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyphenon E (PolyE) - 400 mg (‐)‐epigallocatechin‐3‐gallate (EGCG) per day
Study: 23792649
Drug: Low-dose Tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Tacrolimus QD
Study: 21296768
Drug: Intercostal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal nerve block plus i.v. patient-controlled analgesia with morphine
Study: 19795984
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Study: 19795984
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with facial fillers (poly‐l‐lactic acid or polyacrylamide gel)
Study: 12563891
Drug: Intranasal capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal capsaicin (3 x 10(‐6) mol, dissolved in 70% ethanol)
Study: 3532742
Drug: Intravenous plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plus intracoronary SK
Study: 3532742
Drug: Successful recanalization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful recanalization during intracoronary SK infusion
Study: 3532742
Drug: Persistent coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistent coronary occlusion despite thrombolytic therapy
Study: 15849974
Drug: Drug treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatments for acute manic or depressive episodes
Study: 11818112
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of 50 microg/day transdermal 17beta‐estradiol (TE) administration
Study: 11818112
Drug: 15 days
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 days of 100 microg/day transdermal 17beta‐estradiol (Estraderm‐Ciba) administration
Study: 10385059
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (colloidal bismuth subcitrate, tetracycline, metronidazole) for 2 weeks
Study: 10385059
Drug: Sucralphate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralphate (1 g, q.i.d.) for 4 weeks
Study: 10385059
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg, b.d.) for 4 weeks
Study: 6123330
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg bunitrolol (BU)
Study: 6123330
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methypranol (ME)
Study: 31308556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Intense Pulse Light and topical eflornithine therapy (topical eflornithine applied twice a day and IPL session once a month for 6 months)
Study: 31308556
Drug: Intense Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense Pulse Light therapy alone (IPL monthly sessions for 6 months)
Study: 28372653
Drug: 20ml of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml of 0.75% ropivacaine with 1ml of isotonic saline and intravenous 4mg dexamethasone (Div group, n=20)
Study: 23525419
Drug: 7-day IPC
Normalized name: CAP,IPC VALVE ROCKET #54410
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day IPC (single daily episodes of IPC for 6 days prior to IR)
Study: 23525419
Drug: Celecoxib (cyclooxygenase‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (cyclooxygenase‐2 inhibitor)
Study: 21489168
Drug: Standard concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard concentration intranasal fentanyl (SINF)
Study: 21489168
Drug: Highly concentrated
Normalized name: Recombinant human highly phosphorylated acid alpha-glucosidase
DrugBank: Recombinant human highly phosphorylated acid alpha-glucosidase (DB17673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly concentrated intranasal fentanyl (HINF)
Study: 17230032
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 or 20 mg/day
Study: 7606728
Drug: Deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxyspergualin (DSG) at doses of 50 mg/m2 (dl I) or 150 mg/m2 (dl II and III) administered on days 1-7.
Study: 7606728
Drug: L6 mAb
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: L6 mAb administered at a fixed dose of 200 mg/m2 on days 1-5.
Study: 7606728
Drug: Deoxyspergualin (DSG)
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxyspergualin (DSG) at a starting dose of 150 mg/m2/day recommended for Phase II trials.
Study: 30485123
Drug: Mindfulness-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based treatment protocol
Study: 28027630
Drug: SQ-LNSs (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNSs (20 g daily)
Study: 28027630
Drug: Biscuit (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscuit (3 pieces daily)
Study: 17690809
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol (Experiment 1)
Study: 17690809
Drug: 0.7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g/kg alcohol (Experiment 2)
Study: 15637138
Drug: 4-drug induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug induction treatment with intermediate-dose cytarabine and mitoxantrone salvage treatment
Study: 15637138
Drug: Initial induction
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial induction treatment
Study: 10431340
Drug: Mouth rinse
Normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinse containing amyloglucosidase and glucose oxidase (enzyme solution)
Study: 7648979
Drug: Bile acid
Normalized name: Bile acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acid medication with or without shock‐wave lithotripsy
Study: 28236619
Drug: Acupuncture adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture adjunctive to zolpidem (AAZ)
Study: 28236619
Drug: Biofeedback adjunctive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback adjunctive to zolpidem (BAZ)
Study: 24315664
Drug: 5% CO2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% CO2 inhalation during hyperventilation
Study: 19444092
Drug: Ranolazine 1000
Normalized name: ranolazine 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine 1000 mg twice daily for 6 weeks
Study: 15064019
Drug: 0.5Gy once
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5Gy once daily
Study: 11925292
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate 200 mg
Study: 11925292
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate 100 mg
Study: 11925292
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate 50 mg
Study: 11925292
Drug: Haloperidol decanoate
Normalized name: Haloperidol Decanoate
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol decanoate 25 mg
Study: 326349
Drug: Ornidazole 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole 1.5 g single dose
Study: 29958053
Drug: Curcumin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1 g/d)
Study: 21592308
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg (evening dose) on day 3, followed by 75 mg b.i.d. on day 4
Study: 17000801
Drug: Remifentanil high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil high concentration (8 ng mL(‐1))
Study: 17000801
Drug: Remifentanil low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil low concentration (3 ng mL(‐1))
Study: 10969252
Drug: DTaP-HBV-IPV/Hib (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-HBV-IPV/Hib (mixed administration)
Study: 10969252
Drug: DTaP-HBV-IPV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-HBV-IPV + Hib (separate administration)
Study: 10969252
Drug: Both mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both mixed and separate administration
Study: 1386029
Drug: Goserelin (3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (3.6 mg depot monthly subcutaneously)
Study: 1386029
Drug: Danazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol (200 mg three times a day for 24 weeks)
Study: 6511088
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate (500 mg tablets)
Study: 6511088
Drug: Erythromycin base
Normalized name: Erythromycin base
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin base (500 mg enteric-coated pellets)
Study: 29155123
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro low mixture (LM)
Study: 26019334
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 mg) administered intravenously
Study: 23216417
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + diet beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg diet Squirt)
Study: 23216417
Drug: Alcohol +
Normalized name: Benzyl alcohol + eucalyptus oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol + regular beverage (1.97 ml/kg vodka mixed with 3.94 ml/kg Squirt)
Study: 12690273
Drug: Pleconaril, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pleconaril, 5 mg/kg/dose orally three times a day for 7 days
Study: 8960577
Drug: Non-aspirin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin treatment
Study: 30319652
Drug: QBECO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBECO treatment
Study: 25706882
Drug: Ozanezumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab, a humanised IgG monoclonal antibody against Nogo‐A protein, administered intravenously in a first‐in‐human study.
Study: 25706882
Drug: Ozanezumab, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanezumab, administered intravenously, with one or two doses.
Study: 22738802
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg/day
Study: 22738802
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg/day
Study: 21560631
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily + UDCA 10 mg/kg daily
Study: 9663727
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg daily
Study: 3932054
Drug: Misoprostol 25
Normalized name: Misoprostol 25 microgram vaginal tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 25 micrograms q.i.d. with aspirin 650 mg q.i.d.
Study: 26590023
Drug: Intensive psychotherapy
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychotherapy plus pharmacotherapy
Study: 26590023
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (three-session psycho-educational intervention) plus pharmacotherapy
Study: 26590023
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care plus pharmacotherapy
Study: 24226057
Drug: Earlier ART
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Earlier ART (within 2 weeks after TB treatment initiation)
Study: 24226057
Drug: Later ART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later ART (8-12 weeks after TB treatment)
Study: 22576712
Drug: Synbiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic therapy (Lactobacillus, Bifidobacterium, and galactooligosaccharides) for 8 weeks
Study: 7590485
Drug: Intraperitoneal interferon-alpha
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal interferon-alpha 2b (5-30 x 10(6) units) administered on Day 1 (+/- Day 8)
Study: 7590485
Drug: Intravenous cis-platinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cis-platinum (75 mg/m2) plus cyclophosphamide (750 mg/m2) administered on Day 2
Study: 3918969
Drug: Conventional dose/fraction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose/fraction (180‐200 cGy) X 5 days/week (Group A)
Study: 20576763
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical ciclosporin A
Study: 15663445
Drug: acid etching
Approvals — FDA: no, EMA: no, PMDA: no
Description: acid etching and application of a bonding agent
Study: 12244290
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg and Ketamine 2 mg/kg (MK2)
Study: 12244290
Drug: Midazolam 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.3 mg/kg and Ketamine 1 mg/kg (MK1)
Study: 12244290
Drug: Midazolam 0.5
Normalized name: midazolam 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.5 mg/kg (Control group M)
Study: 10397661
Drug: 5% acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% acyclovir cream (Zovirax cream)
Study: 2271366
Drug: Dilevalol (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (100-400 mg daily)
Study: 389818
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sulphamethizole twice daily
Study: 389818
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim twice daily
Study: 389818
Drug: 410 mg
Normalized name: aspirin 410 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 410 mg sulphadiazine plus 90 mg trimethoprim twice daily
Study: 389818
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg trimethoprim alone
Study: 389818
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sulphamethizole
Study: 389818
Drug: 410 mg
Normalized name: aspirin 410 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 410 mg sulphadiazine plus 90 mg trimethoprim
Study: 25504811
Drug: Biologic disease‐modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic disease‐modifying antirheumatic drugs (DMARDs)
Study: 15055997
Drug: Sitaxsentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxsentan 100 mg once daily
Study: 17335962
Drug: Active magnetic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active magnetic stimulation (Neocontrol), 20 treatments of 20 minutes each over six weeks.
Study: 17335962
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (identical looking/sounding device with deflector plate), 20 treatments of 20 minutes each over six weeks.
Study: 9308642
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood components (not screened for CMV antibody)
Study: 7959579
Drug: Chemotherapy (cisplatinum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatinum and 5-fluorouracil) and radiation followed by resection
Study: 3311054
Drug: bezafibrate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate (200 mg t.i.d.)
Study: 3311054
Drug: colestyramine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: colestyramine (4 g t.i.d.)
Study: 31559844
Drug: Fascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascial therapy (1 session per week for 3 weeks)
Study: 25629321
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg (DexIV)
Study: 25629321
Drug: Perineural dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perineural dexamethasone 8 mg (DexP)
Study: 25629321
Drug: Control (30-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (30-mL bupivacaine 0.5% alone)
Study: 23566943
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (7000 IU daily for 26 weeks)
Study: 20931100
Drug: LOS 150
Normalized name: Rea-Lo 150 MG/ML Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS 150 mg/HCTZ 25 mg
Study: 20931100
Drug: LOS 150
Normalized name: Rea-Lo 150 MG/ML Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOS 150 mg/HCTZ 37.5 mg
Study: 18222735
Drug: Goshuyuto extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshuyuto extract for 1 month, followed by 3 months of goshuyuto in the treatment group.
Study: 15973834
Drug: CSEB applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSEB applied without any cavity preparation
Study: 26901353
Drug: 840 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 840 mg/day DHA
Study: 19148407
Drug: 4% titanium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% titanium tetrafluoride solution (TiF4)
Study: 9805071
Drug: Heberbiovac-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heberbiovac-HB vaccine at 10 g
Study: 9805071
Drug: Heberbiovac-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heberbiovac-HB vaccine at 5 g
Study: 9805071
Drug: Heberbiovac-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heberbiovac-HB vaccine at 2.5 g